Related Experiment Video

Updated: Feb 8, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K

Pediatric CD8+/CD56+ mycosis fungoides with cytotoxic marker expression: A variant with indolent course

Marco Rovaris1, Chiara Colato2, Giampiero Girolomoni1

  • 1Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

Journal of Cutaneous Pathology
|July 4, 2018
PubMed

Insights

This study details a rare pediatric case of CD8+/CD56+ mycosis fungoides in a 10-year-old boy. The condition showed a favorable prognosis with skin-directed treatments, achieving complete remission.

Area of Science:

  • Pediatric Dermatology
  • Oncoimmunology

Background:

  • Mycosis fungoides (MF) is a rare cutaneous T-cell lymphoma, typically affecting adults.
  • Pediatric MF, while uncommon, presents unique diagnostic and therapeutic challenges.

Observation:

  • A 10-year-old boy presented with asymptomatic, erythematous, and scaling plaques on the thigh and trunk.
  • Biopsy revealed CD8+/CD56+ mycosis fungoides with expression of cytotoxic markers (perforin, TIA-1, granzyme B).

Findings:

  • The patient achieved complete remission within 2 months using narrow-band UVB phototherapy and topical corticosteroids.
  • No recurrence was observed during a 2-year follow-up period.

Implications:

  • This case highlights a rare subtype of pediatric MF with a favorable prognosis.
  • Skin-directed therapies demonstrate efficacy in treating pediatric mycosis fungoides, suggesting a good outlook for similar cases.
Keywords:
CD8+ mycosis fungoideschildrencutaneous lymphomascytotoxic immunophenotypemycosis fungoides

More Related Videos

Author Spotlight: High-Throughput Screening of CAR T-Cell Constructs for Enhanced Cytotoxicity and Immunologic Memory09:20

Author Spotlight: High-Throughput Screening of CAR T-Cell Constructs for Enhanced Cytotoxicity and Immunologic Memory

Published on: October 27, 2023

3.2K
Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

1.2K

Related Concept Videos

Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.1K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
317
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
237
What is Gene Expression?01:42

What is Gene Expression?

Overview
Gene expression is the process in which DNA directs the synthesis of functional products, that is, proteins. Cells can regulate gene expression at various stages. It allows organisms to generate different cell types and enables cells to adapt to internal and external factors.
Genetic Information Flows from DNA to RNA to Protein
A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is made up of nucleotides and proteins consist of amino...
196.9K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
305